Regorafenib for cancer

Bibliography

• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005;41:773-84
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-90
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Hedbom S, Steinbild S, Frost A, Phase I study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors [abstract]. J Clin Oncol 2007;25:3593
   Google Scholar
• Mross K, Frost A, Steinbild S, A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012; published online; doi:1078-0432.CCR-11-1900 [pii];10.1158/1078-0432.CCR-11-1900 [doi]
   PubMed Web of Science ®Google Scholar
• Shimizu T, Tolcher AW, Patnaik A, Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors [abstract]. J Clin Oncol 2010;28:3035
   PubMed Web of Science ®Google Scholar
• Kies MS, Blumenschein GR Jr, Christensen O, Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2010;28:7585
   Web of Science ®Google Scholar
• Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009;77:257-71
   PubMed Web of Science ®Google Scholar
• Izzedine H, Ederhy S, Goldwasser F, Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807-15
   PubMed Web of Science ®Google Scholar
• Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009;122:322-8
   PubMed Web of Science ®Google Scholar
• Izzedine H, Massard C, Spano JP, VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46:439-48
   PubMed Web of Science ®Google Scholar
• Torino F, Corsello SM, Longo R, Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009;6:219-28
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2011;78:24-32
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37
   PubMed Web of Science ®Google Scholar
• Eisen T, Joensuu H, Nathan P, Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer [abstract]. J Clin Oncol 2009;27:5033
   Google Scholar
• Eisen T, Joensuu H, Nathan P, Phase II trial of the oral multikinase inhibitor BAY 73-4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC) [abstract]. Eur J Cancer 2009;7:424
   Google Scholar
• Eisen T, Joensuu H, Nathan P, Phase II trial of the oral multikinase inhibitor regorafenib (BAY 73-4506) as first-line therapy in patients with metastatic or unresectable renal cell carcinoma (RCC) [abstract]. Eur J Cancer 2011;47:7141
   Google Scholar
• Jeffers M, Quinn D, Joensuu H, Identification of plasma biomarkers for the multikinase inhibitor regorafenib (BAY 73-4506) in patients (pts) with renal cell cancer (RCC) [abstract and poster update]. Ann Oncol 2010;21:1238
   Google Scholar
• Bolondi L, Tak WY, Gasbarrini A, Phase II safety study of the oral multikinase inhibitor regorafenib (BAY 73-4506) as second-line therapy in patients with hepatocellular carcinoma [abstract]. Eur J Cancer 2011;7:6576
   Google Scholar
• Frost A, Buechert M, Unger C, Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: final results of a dose-escalation study [abstract]. J Clin Oncol 2008;26:2558
   PubMed Web of Science ®Google Scholar
• Strumberg D, Scheulen ME, Schultheis B, Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012; in press
   Google Scholar
• Christensen O, Buechert M, Fasol U, Analysis of plasma biomarkers, DCE-MRI, and KRAS mutations in patients (pts) with advanced colorectal carcinoma (CRC) treated with the multikinase inhibitor regorafenib [abstract]. Ann Oncol 2010;21(Suppl 8):619P
   Google Scholar
• NCT01103323. Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy. Available from: http://clinicaltrials.gov 2011
   Google Scholar
• Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2011; published online; doi:S1533-0028(11)00044-2 [pii];10.1016/j.clcc.2011.05.005 [doi]
   Google Scholar
• Grothey A, Sobrero AF, Siena S, Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies [abstract]. J Clin Oncol 2012;30:LBA 385
   Web of Science ®Google Scholar
• Schultheis B, Folprecht G, Kuhlmann J, Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second line colorectal cancer [abstract]. J Clin Oncol 2011;29:3585
   Google Scholar
• NCT01289821. First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib. Available from: http://clinicaltrials.gov 2011
   Google Scholar
• Dagher R, Cohen M, Williams G, Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-8
   PubMed Web of Science ®Google Scholar
• Demetri GD. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011;38(Suppl 1):S10-19
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Wiebe L, Kasza KE, Maki RG, Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago phase II consortium [abstract]. J Clin Oncol 2008;26:10502
   Web of Science ®Google Scholar
• George S, von Mehren M, Heinrich MC, A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU) [abstract and update from presentation]. J Clin Oncol 2011;29:10007
   Web of Science ®Google Scholar
• Van den Abbeele AD, Tanaka Y, Locascio T, Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx) [abstract]. J Clin Oncol 2011;29:10050
   Google Scholar
• NCT01271712. Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST). Available from: http://clinicaltrials.gov 2011
   Google Scholar
• NCT01187615. Determination of Safety, Efficacy, and Pharmacokinetics of Regorafenib Combined with Pemetrexed and Cisplatin in Patients with Nonsquamous Non-Small Cell Lung Cancer. Available from: http://clinicaltrials.gov 2011
   Google Scholar
• Bergmann L, Eisen T, Joensuu H, Phase II trial of regorafenib (BAY 73-4506) a novel oral multikinase inhibitor as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC) [abstract V459]. Onkologie 2010;33:128
   PubMed Web of Science ®Google Scholar
• NCT01298570. Regorafenib + FOLFIRI Versus Placebo + FOLFIRI as 2nd Line Tx in K-RAS/BRAF Mutant Metastatic Colorectal Cancer. Available from: http://clinicaltrials.gov 2011
   Google Scholar
• NCT01003015. Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma. Available from: http://clinicaltrials.gov 2011
   Google Scholar
• Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010;28:4769-77
   PubMed Web of Science ®Google Scholar
• O'Connor JP, Jackson A, Parker GJ, Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012;9:167-77
   PubMed Web of Science ®Google Scholar
• Mross K, Fasol U, Frost A, DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res 2009;1:5
   PubMedGoogle Scholar